Bioventure Management

About Bioventure Management

Bioventure Management (brand Bioventure) is a German life-sciences investment firm headquartered in Göttingen in Lower Saxony. The firm was founded in 2001, initially operating as a specialised life-sciences advisory firm, and pivoted to direct investment activity in 2011 under the Bioventure Club Deal model. Bioventure does not operate a traditional blind-pool LP fund. Instead, each portfolio company is financed via a dedicated club-deal vehicle structured as an alternative investment fund (AIF) under German regulation. The firm reports having raised close to €70 million across its first six club-deal vehicles with cumulative distributions to investors of approximately €100 million realised through earlier exits. Assets under management as of December 2024 are not publicly disclosed in a single headline figure, but aggregated invested equity exceeds €70 million across active vehicles with portfolio company valuations cumulatively in the hundreds of millions to billions of euros. The leadership team is anchored by Dr. Erik Hoppe (founding partner) and Nico Straub (partner). Bioventure positions itself as a hands-on partner-led investor with active board involvement throughout the investment period.

Investment thesis

Bioventure pursues a lab-to-life thesis: early-stage and pre-IPO biopharmaceutical, medical-technology and cell-therapy companies in Germany whose innovations have the potential to deliver measurable improvements in healthcare outcomes. The firm focuses on three areas: biotechnology and genome editing, medical technology and cell therapies, and nutrition and metabolic medicine. The geographic mandate is concentrated on Germany with every portfolio company to date being German-domiciled or German-founded. Ticket structure is set per club deal with a minimum subscription of €200,000 reserved for semi-professional and professional investors as defined under German Kapitalanlagegesetzbuch (KAGB). Aggregate ticket sizes per portfolio company have historically ranged from low single-digit millions to over €15 million across multiple rounds. The limited partner base is highly concentrated: wealthy entrepreneurial families, family offices and industry experts including former senior executives from major European corporates. This base provides not just capital but operational and scientific input. Value creation is exercised through active supervisory board roles, scientific committee work, recruitment of executive teams and orchestration of clinical and commercial milestones. The firm typically supports a portfolio company across multiple financing rounds within the same club-deal envelope.

Recent activity

Active portfolio holdings include Aphaia Pharma in biotech and metabolic medicine (2018 entry, ongoing follow-on), Provirex in biotech and genome editing (2022), Repairon in cell therapies and regenerative medicine (2025), Aptarion Biotech in biotech and pneumonia therapy and DiaMonTech in medtech and non-invasive glucose monitoring (latest follow-on 2025). Two realised exits are public: Jennewein Biotechnologie in white biotechnology and human-milk oligosaccharides (2020 exit after 2012 entry) and Euroimmun in laboratory diagnostics and medtech (2017 exit after 2013 entry). These two exits delivered the bulk of the cumulative €100 million distributions reported. Detailed buyer names and multiple data available on Pro at €29/month.